Abstract
Rheumatoid arthritis (RA) can be the source of significant pain and functional limitation. The past 20 years have seen a transition in treatment goals away from mere pain management toward disease modification through the suppression of autoimmunity. Disease‐modifying anti‐rheumatic drugs, such as methotrexate and biologic agents, impair disease progression and joint destruction. However, despite these achievements, a substantial subset ofRApatients does not respond to or cannot tolerate current treatments forRA. Scientific insight into the cellular pathways of inflammation has revealed new therapeutic targets for the treatment of autoimmune diseases likeRA. Attention has focused on pathways mediated by Janus kinase (JAK), mitogen‐activated protein kinase (MAPK), and spleen tyrosine kinase (Syk). This review article summarizes the evidence supporting the use of various kinase inhibitors, including the newly approvedJAKinhibitor tofacitinib, in the treatment ofRA.

This publication has 45 references indexed in Scilit: